Anticipated Release: Q3FY25 BCIS-ENBD will provide a ground-based isolation area for personnel infected or suspected of infection of biological organism or infectious disease and allows medical staff to monitor and/or treat while decreasing the risk Read More
Anticipated Release: Q4FY27 Host response based test to predict illness severity. Responding to this opportunity requires membership in the Countering Weapons of Mass Destruction (CWMD) Consortium. This Consortium releases numerous solicitations throughout the year, so even Read More
Anticipated Release: Q3FY25 This effort will solicit multidisciplinary teams for a competition involving prediction of synthetic binders, synthesis of identified binders, and assay development to include, but not limited to, lateral flow assays (LFAs) with Read More
Anticipated Release Date: Q3FY25 This topic aims to provide novel, low-burden masks for the general purpose warfighter utilizing innovative materials and custom manufacturing processes. These materials and processes will make these masks bespoke to users’ Read More
Anticipated Release Date: Q1FY25 New start OTA award for ADTX Responding to this opportunity requires membership in the Countering Weapons of Mass Destruction Consortium. This Consortium releases numerous solicitations throughout the year, so even if this Read More
Anticipated Release Date: Q4FY24 Development of alternate large animal models for biothreats (viral and toxin) and chemical threats. Due to the limited supply of non-human primates, the CBDP is investing in alternative models for threat Read More
Anticipated Release Date: Q4FY24 The prioritizations on broad-spectrum direct-acting antivirals (nucleoside/nucleotide-like compounds and combination therapies) and host-directed broad-spectrum antivirals and antibacterials such as molecules that target host signaling pathways, are involved in entry and replication, Read More
Anticipated Release Date: Q4FY24 Prophylactic and therapeutic medical countermeasures for exposure to naturally occurring, synthetic and/or aerosolized toxins (excluding botulinum and ricin). Efforts would aim to focus on advancing the discovery of: Enabling capabilities for Read More
Anticipated Release Date: Q4FY24 Develop a microphysiological system that realistically mimics human physiological responses to threat exposures for rapid discovery of diagnostic biomarkers. Responding to this opportunity requires membership in the Medical CBRN Defense Consortium. This Consortium Read More
Anticipated Release Date: Q3FY24: Modification of existing Accelerated Antibodies agreement for additional monoclonal antibody prototype. Responding to this opportunity requires membership in the Medical CBRN Defense Consortium. This Consortium releases numerous solicitations throughout the year, so even Read More
NTA is operated by the 501c(3) non-profit Advanced Technology International (ATI). National Technology Alliance (NTA) © 2024 - All rights reserved.